a. IL7Ra signaling potentiates the anti-tumor activity of NK cells. Wang C, Kim SM, Kong LZ, Jang I, Jo S, Lee S, Lee SY, Oh SC, Kim TD. 2025.Under Revision. [Correspondence] 

b. Genetic manipulation of OGT enhances NK cell-mediated cytotoxicity in tumor immunity. Oh SC, Jeon BC, Jang I, Song MR, Hwang H, An D, Yue L, Jung YR, Park, Kim TD. 2025. Under Review. [Correspondence] 

c. Fine-tuning signal strength in CD5 CAR-NK cells for targeted T cell cancer therapy. Jo S, Lee YB, Kim SM, Lee SY, Choi M, Kyun MR, Jeong SY, Lee S, Kim JY, Moon KS, Kim TD. 2025. Under Review. [Correspondence] 

d. Stress-induced self recognition by natural killer cells does not require HLA class I. Lee S, Chae SJ, Jang I, Kim JH, Kim J, Kim TD. Under Review. [Correspondence 

87. Genetic manipulation of OGT enhances NK cell-mediated cytotoxicity in tumor immunity. Oh SC, Jeon BC, Jang I, Song MR, Hwang H, An D, Yue L, Jung YR, Park SK*, Kim TD*. 2025. Journal of Advanced Research. In Press. (* equal). [Correspondence, IF13] 

86. Fine-tuning signal strength in CD5 CAR-NK cells for targeted T cell cancer therapy. Jo S, Lee YB, Kim SM, Lee SY, Choi M, Kyun MR, Jeong SY, Lee S, Kim JY, Moon KS, Kim TD. 2025. Front Immunol. In Press. [Correspondence, IF5.9] 

85. Enhancement of NK cell activity via DNA-sensing inhibition by poxin transgene. Kong LZ, Kim SM, Lee SY, Jang IH, Wang C, Jo S, Oh SC, Lee S, Kim JH, Kim KK, Kim TD. J Adv Res. 2025 Jun. Open Access. [Correspondence, IF 13/JCR8.9%] 

84. Developing CAR-T/NK cells that target EphA2 for non-small cell lung cancer treatment. Kim SM, Lee SY, Kim SI, Bae JY, Hong JT, Jo S, Kim JH, Chung HY, Kim TD. Front Immunol. 2025 Mar 13; 16:1448438. [Correspondence, IF 5.9]  

83. Dynamic O-GlcNAcylation governs long-range chromatin interactions in V(D)J recombination during early B-cell development. Jeon BC, Kim YJ, Park AK, Song MR, Na KM, Lee J, An D, Park Y, Hwang H, Kim TD, Lim J, Park SK. Cell Mol Immunol. 2025 Jan;22(1):68. [Co-author, IF 21.8]

82. Therapeutic potential of anti-ErbB3 chimeric antigen receptor natural killer cells against breast cancer. Lee J, Song J, Yoo W, Choi H, Jung D, Choi E, Jo SG, Gong EY, Jeoung YH, Park YS, Son WC, Lee H, Lee H, Kim JJ, Kim T, Lee S, Park JJ, Kim TD, Kim SH. Cancer Immunol Immunother. 2025 Jan. 3;74(2):73. [Correspondence, IF 4.6] 

81. Transcriptomic landscapes of STING-mediated DNA-sensing reveal cellular response heterogeneity. Kong LZ, Jang IH, Wang C, Lee SY, Kim SM, Oh SC, Lee S, Jo S, Kim JH, Kim KK, Kim TD. Int J Biol Macromol. 2025 Feb;288:138752. [Correspondence, IF 7.7] 

80. Therapeutic effect of TN13 peptide on acute respiratory syndrome and sepsis models in vivo. Byun JE, Lee JW, Choi EJ, Lee J, Yun SH, Park CH, Kim H, Kim MS, Yoon SR, Kim TD, Noh JY, Min SH, Seong HA, Ahn KS, Choi I, Jung H. J. Cli, Med. 2025 Mar; 14(6):1804. [Co-author, IF 3] 

79. 3D Scaffold-Based Culture System Enhances Preclinical Evaluation of Natural Killer Cell Therapy in A549 Lung Cancer Cells. Han EH, Cho SH, Lee SN, Cho MY, Lee H, Lee SY, Ngoc Thi Tran C, Park HS, Min JY, Kim HM, Park MS, Kim TD, Lim YT, Hong KS. ACS Appl Bio Mater. 2024 Nov;7(11):7194. [Co-author, IF 4.7] 

78. B7H6 is the predominant activating ligand driving natural killer cell-mediated killing in liquid tumor patients: Evidence from clinical, in silico, in vitro, and in vivo studies. Lee S, Chae SJ, Jang IH, Oh SC, Kim SM, Lee SY, Kim JH, Ko S, Kim HJ, Kim JK*, Kim TD*. eBiomedicine 2024 Dec; 110:105459. (* equal correspondence). [Correspondence, IF 9.7 / JCR4.76%] 

77. Microfluidics-assisted fabrication of natural killer cell-laden microgel enhances the therapeutic efficacy for tumor immunotherapy. Lee D, Kim SM, Kim D, Beak SY, Yeo SJ, Lee JJ, Cha C, Park SA*, Kim TD*. Materials Today Bio. 2024 June; 26:101055. (* equal correspondence). [Correspondence, , IF 8.8/JCR7.5%]  

76. Modulating lipid nanoparticles with histidinamide-conjugated cholesterol for improved intracellular delivery of mRNA. Jung O, Jung HY, Thuy LT, Choi M, Kim S, Jeon HG, Yang J, Kim SM, Kim TD, Lee E, Kim Y, Choi JS. Advanced Healthcare Materials. 2024 Jun; 13(14):2303857. [Co-author, IF 10.0] 

75. Deficiency of thioredoxin-interacting protein (TXNIP) results in age-related thrombocytopenia due to megakaryocyte oxidative stress. Shin E, Park C, Park T, Chung H, Hwang H, Bak SH, Chung KS, Yoon SR, Kim TD, Choi I, Lee CH, Jung H, Noh JY. J Thromb Heamost. 2024 Mar; 22(3):834. [Co-author, IF 5.5] 

74. STAT1 as a tool for non-invasive monitoring of NK cell activation in cancer. Min JY, Kim HM, Lee H, Cho MY, Park HS, Lee SY, Park MS, Ha SK, Kim D, Jeong HG, Kim TD, Hong KS, Han EH.Commun Biol. 2024 Sep;7(1):1222. [Co-author, IF 5.2] 

73. Harnessing B7-H6 for Anticancer Immunotherapy: Expression, Pathways, and Therapeutic Strategies. Lee S, Kim JH, Jang IH, Jo S, Lee SY, Oh SC, Kim SM, Kong L, Ko J, Kim TD. Int J Mol Sci. 2024 Sep; 25(19):10326. [Correspondence, IF 4.9] 

72. Breakthroughs in cancer immunotherapy: An overview of T cell, NK cell, Mp, and DC-based treatments. Lee S and Kim TD. Int J Mol Sci: 2023 Dec; 24:17634. [Correspondence, IF 4.9] 

71. Understanding nucleic acid sensing and its therapeutic applications. Kong LZ, Kim SM, Wang C, Lee SY, Oh SC, Lee S, Jo S, Kim TD. Experimental and Molecular Medicine. 2023 Nov; 55(11):2320. [Correspondence, IF 9.5] 

70. NK cells encapsulated in micro/macropore-forming hydrogels via 3D bioprinting for tumor immunotherapy. Kim D, Jo S, Lee D, Kim SM, Seok JM, Yeo SJ, Lee JH, Lee JJ, Lee K, Kim TD*, Park SA*. Biomaterials Research. 2023 Jun; 27(1):60 (* equal correspondence). [Correspondence, IF 8.1] 

69. The SpACE-CCM: A facile and versatile cell culture medium-based biosensor for detection of SARS-CoV-2 spike-ACE2 interaction. Ham Y, Cho NC, Kim D, Kim JH, Jo MJ, Jeong MS, Pak BY, Lee S, Lee MK, Chi SW, Kim TD, Jeong NC, Cho S. Biosens Bioelectron. 2023 May; 227:115169. [co-author, IF11.19] 

68. Verproside, the Most Active Ingredient in YPL-001 Isolated from Pseudolysimachion rotundum var. subintegrum, Decreases Inflammatory Response by Inhibiting PKCδ Activation in Human Lung Epithelial Cells. Oh ES, Ryu HW, Kim MO, Lee JW, Song YN, Park JY, Kim DY, Ro H, Lee J, Kim TD, Hong ST, Lee SU, Oh SR. Int J Mol Sci. 2023 Apr;24(8):7229. [co-author, IF4.9] 

67. FTO negatively regulates NK cell killing efficacy. Kim SM, Oh SC, Lee SY, Kong LZ, Lee JH, Kim TD. EMBO Rep. 2023 Apr;24(4): e55681. [Correspondence, IF 6.5 ] 

66. NgR1 is an NK cell inhibitory receptor that destabilizes immunological synapse. Oh SC, Kim SE, Jang IH, Kim SM, Lee SY, Lee SY, Chu IS, Yoon SR, Jung HY, Choi I, Doh JS*, Kim TD*. Nat. Immunol. 2023 Mar;24(3):463 (* equal correspondence). [Correspondence, IF 28.2/JCR1.1%]  

65. A modifiable universal cotinine-chimeric antigen system of NK cells with multiple targets. Kang HY, Lee SY, Kim HM, Lee H, Cho MY, Park HS, Han EH, Chung J, Hong KS*, Choi I*, Kim TD*. Frontiers in Immunol. 2023 Jan;13:1089369 (* equal correspondence). [Correspondence, IF 5.7 ] 

64. The role of IL-7 and IL-7R in cancer pathophysiology and immunotherapy. Wang C, Kong L, Kim SM, Lee SY, Oh SC, Jo SA, Jang I, Kim TD. Int J Mol Sci: 2022 Sep;23(18):10412. [Correspondence, IF 4.9] 

63. Heterotypic cell-in-cell structures between cancer and NK cells are associated with enhanced anticancer drug resistance. Choe YJ, Min JY, Lee H, Lee SY, Kwon J, Kim HJ, Lee J, Kim HM, Park HS, Cho MY, Hyun JY, Kim HM, Chung YH, Ha SK, Jeong HG, Choi I, Kim TD, Hong KS, Han EH. iScience. 2022 Aug;25(9):105017. [co-author, IF4.39] 

62. Aurantii Fructus Immaturus enhances natural killer cytolytic activity and anticancer efficacy in vitro and in vivo. Park A, Yang Y, Lee Y, Jung H, Kim TD, Noh JY, Lee S, Yoon SR. Frontiers in Med. 2022 Aug;9:973681. [co-author, IF3.9] 

61. Ginsenoside 20(R)-Rg3 enhances natural killer cell activity by increasing activating receptor expression through the MAPK/ERK signaling pathway. Lee Y, Park A, Park YJ, Jung H, Kim TD, Noh JY, Choi I, Lee S, Ran Yoon S. Int Immunopharmacol. 2022 Jun;107:108618. [co-author, IF 4.8] 

60. Tryptophanyl-tRNA synthetase as a potential therapeutic target. Ahn YH, Oh SC, Zhou S, Kim TD. Int J Mol Sci: 2021 Apr;22(9):4523. [Correspondence, IF 4.9] 

59. RNA demethylation by FTO stabilized the FOXJ1 mRNA for proper motile ciliogenesis. Kim H*, Lee YS, Kim SM, Jang S, Choi H, Lee JW, Kim TD*, Kim VN*. Developmental Cell: 2021 Apr;56(8):1118. (* equal correspondence). [Correspondence, IF 11.5/JCR2.56%] 

58. Transforming Growth Factor β Inhibits MUC5AC Expression by Smad3/HDAC2 Complex Formation and NF-κB Deacetylation at K310 in NCI-H292 Cells. Lee SU, Kim MO, Hong ST*, Kim TD*. Mol Cells: 2021 Jan;44(1):38. (* equal correspondence). [Correspondence, IF 3.7] 

57. TXNIP Regulates Natural Killer Cell-Mediated Innate Immunity by Inhibiting IFN-γ Production during Bacterial Infection. Kim DO, Byun JE, Kim WS, Kim MJ, Choi JH, Kim H, Choi E, Kim TD, Yoon SR, Noh JY, Park YJ, Lee J, Cho HJ, Lee HG, Min SH, Choi I, Jung H. Int J Mol Sci. 2020 Dec;21(24):9499. [co-author, IF 4.9] 

56. The Gata1 low murine megakaryocyte-erythroid progenitor cells expand robustly and alter differentiation potential. Shin E, Jeong JG, Chung H, Jung H, Park C, Yoon SR, Kim TD, Lee SJ, Choi I, Noh JY. Biochem Biophys Res Commun. 2020 Jul;528(1):46. [co-author, IF 2.5] 

55. A three-dimensional hyaluronic acid-based niche enhances the therapeutic efficacy of human natural killer cell-based cancer immunotherapy. Ahn YH, Long R, Kim SM, Seo SH, Jung CR, Kim DS, Noh JY, Lee SY, Lee HS, Cho MY, Jung HY, Yoon SR, Kim JE, Kim SH, Shin IW, Shin HS, Hong KS, Lim YT*, Choi*, Kim TD*. Biomaterials: 2020 Jul;247:119960. (* equal correspondence). [Correspondence, IF 12.8] 54. Toll-like receptors in natural killer cells and their application for immunotherapy. Noh JY, Yoon SR, Kim TD, Choi I. Jung HY. J Immunol Res: 2020 Jan;2020(1):2045860. [co-author, IF 3.41] 

53. Thioredoxin-Interacting Protein Promotes Phagosomal Acidification Upon Exposure to Escherichia coli Through Inflammasome-Mediated Caspase-1 Activation in Macrophages. Yoon SJ, Jo DH, Park SH, Park JY, Lee YK, Lee MS, Min JK, Jung H, Kim TD, Yoon SR, Chung SW, Kim JH, Choi I, Park YJ. Front Immunol. 2019 Nov;10:2636. [co-author, IF 5.7] 

52. Pathogenesis, early diagnosis, and therapeutic management of alcoholic liver disease. Kong LZ, Chandimali N, Han YH, Lee DH, Kim JS, Kim SU, Kim TD, Jeong DK, Sun HN, Lee DS, Kwon T. Int J Mol Sci. 2019 Jun;20(11):2712. [co-author, IF 4.9] 

51. Indoleamine-2,3-Dioxygenase in Thyroid Cancer Cells Suppresses Natural Killer Cell Function by Inhibiting NKG2D and NKp46 Expression via STAT Signaling Pathways. Park A, Yang Y, Lee Y, Kim MS, Park YJ, Jung H, Kim TD, Lee HG, Choi I, Yoon SR. J Clin Med. 2019 Jun;8(6):842. [co-author, IF 3.0] 

50. TXNIP regulates AKT-mediated cellular senescence by direct interaction under glucose-mediated metabolic stress. Huy H, Song HY, Kim MJ, Kim WS, Kim DO, Byun JE, Lee J, Park YJ, Kim TD, Yoon SR, Choi EJ, Lee CH, Noh JY, Jung H, Choi I. Aging Cell. 2018 Dec;17(6):e12836. [co-author, IF 8.0] 

49. TLR4/NF-κB axis induces fludarabine resistance by suppressing TXNIP expression in acute myeloid leukemia cells. Huy H, Kim TD, Kim WS, Kim DO, Byun JE, Kim MJ, Park YJ, Yoon SR, Noh JY, Lee J, Lee KH, Choi I, Jung H. Biochem Biophys Res Commun. 2018 Nov;506(1):33. [co-author, IF 2.5] 

48. Prostaglandin E2 Secreted by Thyroid Cancer Cells Contributes to Immune Escape Through the Suppression of Natural Killer (NK) Cell Cytotoxicity and NK Cell Differentiation. Park A, Lee Y, Kim MS, Kang YJ, Park YJ, Jung H, Kim TD, Lee HG, Choi I, Yoon SR. Front Immunol. 2018 Aug;9:1859. [co-author, IF 5.7] 

47. MicroRNA-150 controls differentiation of intraepithelial lymphocytes via TGF-b receptor II expression. Seo SH, Jang MS, Kim DJ, Kim SM, Oh SC, Jung CR, Park Y, Ha SJ, Jung HY, Park YJ, Yoon SR, Cho I*, Kim TD*. J Allergy Clin Immunol. 2018. Apr;140(4):1382. (* equal correspondence). [Correspondence, IF 11.4] 

46. Ginsenoside Rg3 ameliorated HFD-induced hepatic steatosis through downregulation of STAT5-PPARγ. Lee JB, Yoon SJ, Lee SH, Lee MS, Jung H, Kim TD, Yoon SR, Choi I, Kim IS, Chung SW, Lee HG, Min JK, Park YJ. J Endocrinol. 2017 Dec;235(3):223. [co-author, IF 3.9] 

45. miR-150-Mediated Foxo1 Regulation Programs CD8+ T Cell Differentiation. Ban YH, Oh SC, Seo SH, Kim SM, Choi IP, Greenberg PD, Chang J, Kim TD*, Ha SJ*. Cell Rep. 2017 Sep;20(11):2598. (* equal correspondence). [Correspondence, IF 7.5] 

44. MicroRNA-150 modulates intracellular Ca 2+ levels in naïve CD8 + T cells by targeting TMEM20. Kim TD*, Jung HR, Seo SH, Oh SC, Ban Y, Tan X, Min Kim J, Hyun Lee S, Koh DS, Jung H, Park YJ, Ran Yoon S, Doh J, Ha SJ, Choi I*, Greenberg PD*. Sci Rep. 2017 Jun;7(1):2623. (* equal correspondence). [Correspondence, IF 3.8] 

43. Suppressor of Cytokine Signaling 2 Negatively Regulates NK Cell Differentiation by Inhibiting JAK2 Activity. Kim WS, Kim MJ, Kim DO, Byun JE, Huy H, Song HY, Park YJ, Kim TD, Yoon SR, Choi EJ, Jung H, Choi I. Sci Rep. 2017 Apr;7(1):46153. [coauthor, IF 3.8]

 42. Macrophage migration inhibitory factor interacts with thioredoxin-interacting protein and induces NF-κB activity. Kim MJ, Kim WS, Kim DO, Byun JE, Huy H, Lee SY, Song HY, Park YJ, Kim TD, Yoon SR, Choi EJ, Ha H, Jung H, Choi I. Cell Signal. 2017 Jun;34:110. [co-author, IF 4.4] 

41. Thioredoxin-interacting protein regulates haematopoietic stem cell ageing and rejuvenation by inhibiting p38 kinase activity. Jung H, Kim DO, Byun JE, Kim WS, Kim MJ, Song HY, Kim YK, Kang DK, Park YJ, Kim TD, Yoon SR, Lee HG, Choi EJ, Min SH, Choi I. Nat Commun. 2016. Dec;7(1):13674. [co-author, IF 16.6] 

40. Reprogramming of mouse embryonic fibroblasts to mouse hematopoietic progenitor cells. Song HY, Suh HW, Kim YK, Kim WS, Yun SH, Levantini E, Jung HY, Yoon SR, Kim TD, Park YJ, Choi I. Cell Stem Cell Regen Med. 2016 Apr;2(1):108. [coauthor, IF 3.806] (ISSN: 2472-6990) 

39. Heterogeneous ribonucleoprotein R regulates arylalkylamine N-acetyltransferase synthesis via internal ribosomal entry sitemediated translation in a circadian manner. Lee HR, Kim TD, Kim HJ, Jung Y, Lee D, Lee KH, Kim DY, Woo KC, Kim KT. J Pineal Res. 2015 Nov;59(4):518. [2 nd author, IF 8.3] 

38. Osteoporotic bone of miR-150-deficient mice: Possibly due to low serum OPG-mediated osteoclast activation. Choi SW, Lee SU, Kim EH, Park SJ, Choi I, Kim TD*, Kim SH*. Bone Rep. 2015 Jun;3:5. (* equal correspondence). [Correspondence, IF 2.1] 

37. Ginsenoside Rg3 regulates S-nitrosylation of the NLRP3 inflammasome via suppression of iNOS. Yoon SJ, Park JY, Choi S, Lee JB, Jung H, Kim TD, Choi I, Shim S, Park JY. Biochem Biophys Res Commun. 2015. Aug;463(4):1184. [co-author, IF 2.5] 

36. Understanding of molecular mechanisms in natural killer cell therapy. Yoon SR*, Kim TD*, Choi I. Exp Mol Med. 2015. Feb;47(2): e141. (* equal contribution). [1 st author, IF 9.5] 

35. Integrated mRNA-MicroRNA Profiling of Human NK Cell Differentiation Identifies MiR-583 as a Negative Regulator of IL2Rγ Expression. Yun S, Lee SU, Kim JM, Lee HJ, Song HY, Kim YK, Jung H, Park YJ, Yoon SR, Oh SR, Kim TD*, Choi I*. PLos One. 2014 Oct;9(10):e108913. (* equal correspondence). [Correspondence, IF 2.9] 

34. An increased level of IL-6 suppresses NK cell activity in peritoneal fluid of patients with endometriosis via regulation of SHP-2 expression. Kang YJ, Jung IC, Park A, Park YJ, Jung H, Kim TD, Lee HG, Choi I, Yoon SR. Human Reprod. 2014 Oct;29 (10): 2176. [co-author, IF 6.0] 

33. MicroRNA-150 regulates the cytotoxicity of natural killers by targeting perforin-1. Kim N, Kim M, Yun S, Doh J, Greenberg PD, Kim TD⋆ , Choi I ⋆ . J Allergy Clin Immunol. 2014 Jul;134 (1):195. (* equal correspondence). [Correspondence, IF 11.4] 

32. TXNIP deficiency exacerbates endotoxic shock via the induction of excessive nitric oxide synthesis. Park YJ, Yoon SJ, Suh HW, Kim DO, Park JR, Jung H, Kim TD, Yoon SR, Min JK, Na HJ, Lee SJ, Lee HG, Lee YH, Lee HB, Choi I. PLoS Pathog. 2013 Oct;9(10):e10036. [co-author, IF 5.5]

31. TXNIP interacts with hEcd to increase p53 stability and activity. Suh HW, Yun S, Song H, Jung H, Park YJ, Kim TD, Yoon SR, Choi I. Biochem Biophys Res Commun. 2013 Aug;438(2):264. [co-author, IF 2.5] 

30. TXNIP maintains the hematopoietic cell pool by switching the function of p53 under oxidative stress. Jung H, Kim MJ, Kim DO, Kim WS, Yoon SJ, Park YJ, Yoon SR, Kim TD, Suh HW, Yun S, Min JK, Lee HG, Lee YH, Na HJ, Lee DC, Kim HC, Choi I. Cell Metab. 2013 Jul; 18(1):75. [co-author, IF 27.7] 

29. VDUP1 exacerbates bacteremic shock in mice infected with Pseudomonas aeruginosa. Piao ZH, Kim MS, Jeong M, Yun S, Lee SH, Sun HN, Song HY, Suh HW, Jung H, Yoon SR, Kim TD, Lee YH, Choi I. Cell Immunol. 2012 Nov;280(1):1. [coauthor, IF 3.7]

 28. Abrogation of SRC homology region 2 domain-containing phosphatase 1 in tumor-specific T cells improves efficacy of adoptive immunotherapy by enhancing the effector function and accumulation of short-lived effector T cells in vivo. Stromnes IM, Fowler C, Casamina CC, Georgopolos CM, McAfee MS, Schmitt TM, Tan X, Kim TD, Choi I, Blattman JN, Greenberg PD. J Immunol. 2012 Aug;189(4):1812. [co-author, IF 3.6] 

27. Cryptotanshinone and tanshinone IIA enhance IL-15-induced natural killer cell differentiation. Kim WS, Kim DO, Yoon SJ, Kim MJ, Yoon SR, Park YJ, Jung H, Kim TD, Kwon BM, Choi I. Biochem Biophys Res Commun. 2012 Aug;425(2):340. [co-author, IF 2.5] 

26. Rhythmic interaction between Period1 mRNA and hnRNP Q leads to cirdadian time-dependent translation. Lee KH, Woo KC, Kim DY, Kim TD, Shin J, Park SM, Jang SK, Kim KT. Mol Cell Biol. 2012;32(3):717. [co-author, IF 3.2] 

25. Human microRNA-27a* targets Prf1 and GzmB expression to regulate NK cell cytotoxicity. Kim TD, Lee SU, Yun S, Sun HN, Lee SH, Kim JW, Kim HM, Park SK, Lee CW, Yoon SR, Greenberg PD, Choi I. Blood. 2011 Nov;118(20):5476. [1 st author, IF 21.1] 

24. IL-15-induced IL-10 increases the cytolytic activity of human natural killer cells. Park JY, Lee SH, Yoon SR, Park YJ, Jung H, Kim TD*, Choi I*. Mol Cells. 2011 Nov;32(3):265 (* equal correspondence). [Correspondence, IF 3.7] 

23. Modulation of exosome-mediated mRNA turnover by interaction of GTP-binding protein 1 (GTPBP1) with its target mRNAs. Kim TD*, Woo KC*, Lee KH, Kim DY, Kim S, Lee HR, Kang HJ, Chung SJ, Senju S*, Nishimura Y, Kim KT. FASEB J. 2011 Nov; 25(8):2757. (* equally contributed). [1 st author, IF 4.4] 

22. TOX regulates the differentiation of human natural killer cells from hematopoietic stem cells in vitro. Yun S, Lee SH, Yoon SR, Kim MS, Piao ZH, Myung PK, Kim TD, Jung H, Choi I. Immunol Lett. 2011 Apr;136(1):29. [co-author, IF 3.3] 

21. hnRNP Q and PTB modulate the circadian oscillation of mouse Rev-erb alpha via IRES-mediated translation. Kim DY, Woo KC, Lee KH, Kim TD, Kim KT. Nucleic Acids Res. 2010 Nov;38(20):7068. [co-author, IF 16.6] 

20. Vitamin D3 upregulated protein 1 suppresses TNF-α-induced NF-κB activation in hepatocarcinogenesis. Kwon HJ, Won YS, Suh HW, Jeon JH, Shao Y, Yoon SR, Chung JW, Kim TD, Kim HM, Nam KH, Yoon WK, Kim DG, Kim JH, Kim YS, Kim DY, Kim HC, Choi I. J Immunol. 2010 Oct;185(7):3980. [co-author, 3.6] 

19. Suppressor of cytokine signaling 2 regulates IL-15-primed human NK cell function via control of phosphorylated Pyk2. Lee SH, Yun S, Piao ZH, Jeong M, Kim DO, Jung H, Lee J, Kim MJ, Kim MS, Chung JW, Kim TD, Yoon SR, Greenberg PD, Choi I. J Immunol. 2010 Jul;185(2):917. [co-author, IF 3.6] 

18. YC-1 enhances natural killer cell differentiation from hematopoietic stem cells. Yun S, Lee SH, Kang YH, Jeong M, Kim MJ, Kim MS, Piao ZH, Suh HW, Kim TD, Myung PK, Yoon SR, Choi I. Int Immunopharmacol. 2010 Apr;10(4):481. [co-author, IF 4.8] 

17. Circadian amplitude of cryptochrome 1 is modulated by mRNA stability regulation via cytoplasmic hnRNP D oscillation. Woo KC, Ha DC, Lee KH, Kim DY, Kim TD, Kim KT. Mol Cell Biol. 2010 Jan;30(1):197. [co-author, IF 3.2 

16. RasGRP1 is required for human NK cell function. Lee SH, Yun S, Lee J, Kim MJ, Piao ZH, Jeong M, Chung JW, Kim TD, Yoon SR, Greenberg PD, Choi I. J Immunol. 2009 Dec;183(12):7931. [co-author, IF 3.6] 

15. Tumor necrosis factor-alpha enhances IL-15-induced natural killer cell differentiation. Lee J, Lee SH, Shin N, Jeong M, Kim MS, Kim MJ, Yoon SR, Chung JW, Kim TD, Choi I. Biochem Biophys Res Commun. 2009 Sep;386(4):718. [co-author, IF 2.5] 

14. Thioredoxin-interacting protein regulates hematopoietic stem cell quiescence and mobilization under stress conditions. Jeong M, Piao ZH, Kim MS, Lee SH, Yun S, Sun HN, Yoon SR, Chung JW, Kim TD, Jeon JH, Lee J, Kim HN, Choi JY, Choi I. J Immunol. 2009 Aug;183(4):2495. [co-author, IF 3.6] 

13. Post-transcriptional Regulation of NK Cell Activation. Kim TD, Park JY, Choi I. Immune Network 2009 Aug;9(4):115. [1 st author, IF 4.3] 

12. VDUP1 potentiates Ras-mediated angiogenesis via ROS production in endothelial cells. Piao ZH, Yoon SR, Kim MS, Jeon JH, Lee SH, Kim TD, Lee HG, Bae KH, Min JK, Chung SJ, Kim M, Cho YS, Oh DB, Park SY, Chung JW, Choi I. Cell Mol Biol. 2009 Feb;55(4):1096. [co-author, IF 1.6] 

11. Mouse period 2 mRNA circadian oscillation is modulated by PTB-mediated rhythmic mRNA degradation. Woo KC, Kim TD, Lee KH, Kim DY, Kim W, Lee KY, Kim KT. Nucleic Acids Res. 2009 Jan;37(1):26. [2 nd author, IF 16.6] 

10. Expression of Gpnmb in NK cell development from hematopoietic stem cells. Shin NR, Lee JW, Jeong MR, Kim MS, Lee SH, Yoon SR, Chung JW, Kim TD, Choi I. Immune Network 2008 Jun;8(2): 53. [co-author, IF 4.3] 

9. Rhythmic control of AANAT translation by hnRNP Q in circadian melatonin production. Kim TD, Woo KC, Cho S, Ha DC, Jang SK, Kim KT. Genes Dev. 2007 Apr; 21(7):797. Cover story, Featured News released in International Presses. [1 st author, IF 7.5] 

8. BiP internal ribosomal entry site activity is controlled by heat-induced interaction of NSAP1. Cho S, Park SM, Kim TD, Kim JH, Kim KT, Jang SK. Mol Cell Biol. 2007 Nov; 27(1):368. [co-author, IF 3.2] 

7. Essential role of 3'-untranslated region-mediated mRNA decay in circadian oscillations of mouse Period3 mRNA. Kwak E, Kim TD, Kim KT. J Biol Chem. 2006 Jul;281(28):19100-6. [2 nd author, IF 4.0] 

6. Rhythmic expression of adenylyl cyclase VI contributes to the differential regulation of serotonin N-acetyltransferase by bradykinin in rat pineal glands. Han S, Kim TD, Ha DC, Kim KT. J Biol Chem. 2005 Nov;280(46):38228. [2 nd author, IF 4.0] 

5. Rhythmic serotonin N-acetyltransferase mRNA degradation is essential for the maintenance of its circadian oscillation. Kim TD, Kim JS, Kim JH, Myung J, Chae HD, Woo KC, Jang SK, Koh DS, Kim KT. Mol Cell Biol. 2005 Apr;25(8):3232. [1 st author, IF 3.2] 

4. Sensitization of epidermal growth factor-induced signaling by bradykinin is mediated by c-Src. Implications for a role of lipid microdomains. Hur EM, Park YS, Lee BD, Jang IH, Kim HS, Kim TD, Suh PG, Ryu SH, Kim KT. J Biol Chem. 2004 Feb;279(7):5852. [co-author, IF 4.0] 

3. Heterogeneous nuclear ribonucleoprotein C modulates translation of c-myc mRNA in a cell cycle phase-dependent manner. Kim JH, Paek KY, Choi K, Kim TD, Hahm B, Kim KT, Jang SK. Mol Cell Biol. 2003 Nov;23(2):708. [co-author, IF 3.2] 

2. Pharmacological characterization of adenosine receptors in PGT-beta mouse pineal gland tumour cells. Suh BC, Kim TD, Lee JU, Seong JK, Kim KT. Br J Pharmacol. 2001 Sep;134(1):132. [2 nd author, IF 6.8] 

1. Differential regulation of P2Y(11) receptor-mediated signalling to phospholipase C and adenylyl cyclase by protein kinase C in HL-60 promyelocytes. Suh BC, Kim TD, Lee IS, Kim KT. Br J Pharmacol. 2000 Oct;131(3):489. [2 nd author, IF 6.8]